Clinical trial Recruiting at 2 sites Interventional Ages 18 and up

Examining how gadolinium contrast agents are excreted in urine after MRI

Official title: Kinetics of Urinary Excretion of Gadolinium Contrast Agents Used in MRI Examinations

Run by Centre Hospitalier Régional Metz-Thionville · NCT06191731 · Data updated 2026-11-12

This study is testing how well patients can get rid of gadolinium contrast agents in their urine after an MRI to help find better ways to manage waste from these substances.

More Magnetic Resonance Imaging trials

Quick facts

Study typeInterventional
Ages18 Years and up
SexAll
Enrollment60 (estimated)
SponsorCentre Hospitalier Régional Metz-Thionville
Academic / other
Locations2 sites (Metz, Grand Est and 1 other locations)
StatusRecruiting
StartedApril 12, 2024
Main results expectedApril 12, 2028
Study endsApril 12, 2028
Registry record updatedAugust 21, 2026
Trial IDNCT06191731 on ClinicalTrials.gov

Is this trial a fit for you?

Likely a good fit

Ideal candidates for this study are adults over 18 years old who have a prescription for an MRI with gadolinium-based contrast agents.

Probably not a fit

Patients with known allergies to gadolinium contrast agents, severe renal impairment, or those unable to urinate independently may not benefit from this study.

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This study aims to investigate the urinary excretion kinetics of gadolinium contrast agents (Gd-CAs) used in MRI examinations. Patients who have been prescribed an MRI with Gd-CAs will provide blood and urine samples before and after the injection of the contrast agent. The goal is to assess the feasibility of recovering gadolinium from urine to prevent environmental contamination, as current wastewater treatment processes do not eliminate these compounds effectively. This research could lead to improved protocols for managing gadolinium waste in medical settings.

Why it matters

Potential benefit: If successful, this study could lead to better environmental management of gadolinium contrast agents used in MRI, reducing their impact on freshwater ecosystems.

How similar studies have gone: While the approach of recovering gadolinium from urine is novel, previous studies have highlighted the environmental concerns associated with gadolinium contrast agents, indicating a need for such research.

Who can join: the full rules

Show full inclusion / exclusion criteria
Inclusion Criteria:

Patients:

* over 18 years of age
* with a prescription for MRI with gadolinium-based contrast agents (Gd-CAs) injection validated by a radiologist
* affiliated with a health insurance plan
* have signed an informed consent form

Exclusion Criteria:

* Patients:
* with known allergy to gadolinium-based contrast agents (Gd-CAs)
* with known severe renal impairment (GFR \< 30 mL/min)
* on dialysis
* with urinary incontinence
* with an ongoing urinary tract infection
* under hydric or hydrosodic restriction
* unable to urinate independently
* Protected persons (under guardianship, curatorship or safeguard of justice)
* Pregnant or breast-feeding women

Where it's running

  • CHR Metz-Thionville/Hopital de Mercy
    Metz, Grand Est, France
    Recruiting
  • CHR Metz-Thionville / Hopital Bel Air
    Thionville, France
    Recruiting

Study contacts

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

How to take part

  1. Review the eligibility criteria above with your treating physician.
  2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
  3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.
Last reviewed 2026-11-14 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.